To assess effectiveness (Eligible to the Next Treatment-ENT CR and suficient performance status to the nexttreatment, PFS and OS) and security (Early Mortality) of cytarabine and anthracycline (“7 + 3”regimen)….Subgroups analyzed were about FTL3 and NPM1 mutations....It was a retrospective analysis of all the cases of non-promyelocytic AML ....There were 21% and 11% patients with FLT3-ITD and NPM1 mutations, respectively....The median of PFS and OS were 3.6 and 8.2 months respectively. Patients with FLT3mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes....Patients with FLT3 mutation, platelet < 20.000 and leukocytes < 10.000 had poor outcomes.